Mallinckrodt and Terumo Blood and Cell Technologies Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Chronic Graft Versus Host Disease (cGvHD) in Adults
– In a dual-review process, two independent advisory committees to the Australian Minister for Health recommended reimbursement based on a favorable clinical and cost-effectiveness comparison – DUBLIN and LAKEWOOD, Colo., Oct. 28, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global ...
2021-10-28 05:48
1979
Mallinckrodt Receives Approval in Japan of the CELLEX® Extracorporeal Photopheresis System for Treatment of Chronic Graft Versus Host Disease
DUBLIN, Jan. 28, 2021 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, announced today thatJapan's Ministry of Health, Labour and Welfare (MHLW) approved the CELLEX® extracorporeal photopheresis (ECP) system for the treatment of steroid-resistant or intolerant chronic graft...
2021-01-28 09:00
4552
